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Abstract 
Objective: To advise pediatricians, neonatologists, pulmonologists, pediatric pulmonolo-
gists, and other professionals in the area on the main indications and characteristics of 
long-term home oxygen therapy in children and adolescents.
Data source: A literature search was carried out in the MEDLINE/PubMed database (1990 
to 2011). Additionally, references from selected studies were included. As consistent 
scientific evidence does not exist for many aspects, some of the recommendations were 
based on clinical experience. 
Data synthesis: Long-term home oxygen therapy has been a growing practice in pediatric 
patients and is indicated in bronchopulmonary dysplasia, cystic fibrosis, bronchiolitis 
obliterans, interstitial lung diseases, and pulmonary hypertension, among others. The 
benefits are: decrease in hospitalizations, optimization of physical growth and neu-
rological development, improvement of exercise tolerance and quality of sleep, and 
prevention of pulmonary hypertension/cor pulmonale. The levels of oxygen saturation 
indicative for oxygen therapy differ from those established for adults with chronic 
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Recomendações para oxigenoterapia domiciliar prolongada em crianças e adolescentes
Resumo 
Objetivo: Orientar pediatras, neonatologistas, pneumologistas, pneumologistas pediátri-
cos e outros profissionais envolvidos na área sobre as principais indicações e as particu-
laridades da oxigenoterapia domiciliar prolongada em crianças e adolescentes.
Fontes dos dados: Pesquisa bibliográfica na base de dados MEDLINE/PubMed (1990 a 
2011). Adicionalmente, referências de estudos selecionados foram incluídas. Como para 
muitos dos aspectos não existem evidências científicas consistentes, algumas reco-
mendações citadas foram feitas com base em experiência clínica.
Síntese dos dados: Oxigenoterapia domiciliar prolongada tem sido uma prática crescente 
nos pacientes pediátricos e se encontra indicada em casos de displasia broncopulmonar, 
fibrose cística, bronquiolite obliterante, pneumopatias intersticiais, hipertensão pulmo-
nar, etc. Ressaltam-se como benefícios: redução de internações, otimização do cresci-
mento físico e do desenvolvimento neurológico, melhora da tolerância ao exercício e da 
qualidade do sono e prevenção da hipertensão pulmonar/Cor pulmonale. Os níveis de 
saturação de oxigênio indicativos para a oxigenoterapia diferem dos estabelecidos para 
adultos com doença pulmonar obstrutiva crônica e variam de acordo com a doença e 
faixa etária. Para a avaliação da saturação de oxigênio, utiliza-se a oximetria de pulso, 
sendo a gasometria arterial dispensável. Há três fontes de oxigênio disponíveis: cilindros 
gasosos, oxigênio líquido e concentradores de oxigênio. Os fluxos utilizados costumam 
ser menores, assim como o número de horas/dia necessários, quando comparados ao uso 
em adultos. Em algumas doenças há melhora, e a suspensão do oxigênio é possível.
Conclusões: Oxigenoterapia domiciliar prolongada é uma terapêutica cada vez mais 
comum em pediatria e suas indicações são numerosas. Há particularidades relevantes 
quando comparada aos adultos em relação às indicações, modo de uso e monitorização.
© 2013 Sociedade Brasileira de Pediatria. Publicado por Elsevier Editora Ltda.  
Todos os direitos reservados.
Introduction
Long-term home oxygen therapy (LTHOT) has become an 
increasingly common practice, and many patients benefit 
from its use. It has several clinical and physiological ben-
efits, as well as greater comfort for patients and significant 
cost reduction when compared to hospitalizations. 
Currently, in the United States, 1,000,000 patients 
receive home oxygen therapy, which is equivalent to 241 
patients per 100,000 inhabitants; its annual cost exceeds 
US$ 2,000,000,000.1 
The number of children who need LTHOT is increasing 
worldwide, including in Brazil.2-4 To illustrate how this form 
of treatment is being incorporated into pediatric practice, 
bronchopulmonary dysplasia (BPD) and cystic fibrosis (CF) 
can be mentioned. The great advances in neonatology have 
increased the survival of very premature patients, and 
despite new neonatal approaches, BPD still has significant 
importance, and many of these patients are discharged 
on oxygen treatment. In the case of CF, the evolution of 
treatment associated with improved nutrition has increased 
the survival of these patients, but some require LTHOT in 
advanced stages of the disease, or while waiting for a lung 
transplant.
The use of LTHOT in pediatric patients has several special 
characteristics and important differences when compared 
to the use in adults. The present guidelines aim to stan-
dardize the use of LTHOT in pediatric patients for several 
clinical situations associated with chronic hypoxemia in 
patients who do not require assisted ventilation. As many 
aspects do not have consistent scientific evidence, some of 
the recommendations were based on clinical experience. 
obstructive pulmonary disease, and vary according to age and disease. Pulse oximetry 
is used to evaluate oxygen saturation; arterial blood gas is unnecessary. There are three 
available sources of oxygen: gas cylinders, liquid oxygen, and oxygen concentrators. The 
flows used are usually smaller, as are the number of hours/day needed when compared 
to the use in adults. Some diseases show improvement and oxygen therapy discontinu-
ation is possible.
Conclusions: Long-term home oxygen therapy is increasingly common in pediatrics and 
has many indications. There are relevant particularities when compared to its use in 
adults, regarding indications, directions for use, and monitoring.
© 2013 Sociedade Brasileira de Pediatria. Published by Elsevier Editora Ltda.  
All rights reserved.
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Effects of chronic hypoxemia
The main effects of chronic hypoxemia occur in the 
cardiovascular system, which responds with pulmonary 
vasoconstriction in unventilated localized areas, in order 
to maintain the ventilation/perfusion ratio. This mecha-
nism, however, has a deleterious effect when there is 
diffuse alveolar hypoxia, as a generalized pulmonary 
vasoconstriction leads to pulmonary hypertension. This 
overload to the right ventricle results in cor pulmonale, 
with decreased myocardial contractility and cardiac out-
put and subsequent right heart failure. Polycythemia can 
occur in this situation, leading to a worsening of pulmo-
nary hypertension.
Chronic hypoxemia also leads to systemic involvement, 
such as deficit in the weight-height gain and retardation in 
the neurological and psychomotor development, as well a 
decrease in the quality of sleep. 
Effects of oxygen therapy
Two classic studies in adult patients with chronic obstruc-
tive pulmonary disease (COPD) in the early 1980s formed 
the scientific basis for LTHOT. The “Nocturnal Oxygen 
Therapy Trial”, an American study conducted in 1980, 
compared a group receiving oxygen (O2) for 24 hours/day 
with another receiving O2 for 12 hours at night: mortality 
rate in the first group was 11.9%/year and in the second, 
20.6%/year.5 In the following year, a British study com-
pared a group that received O2 for 15 hours/day with a 
control group that received no O2: mortality rate in the 
first was 12%/year and in the control group, 29%/year.6 
Since then, LTHOT has been accepted by the scientific 
community and recommended for diseases that cause 
chronic hypoxemia. 
The physiological and clinical beneficial effects of LTHOT 
were confirmed in several other studies.7-9 
Physiological effects
•  Increase in PaO2, improving the transport and release of 
O2 to tissues
• Hematocrit normalization
•  Decrease in the pulmonary artery pressure, preventing 
the progression of pulmonary hypertension 
• Increase in the right ventricle performance
• Prevention of cor pulmonale or its progression
Clinical effects
• Improvement of cognitive function 
• Improvement of sleep efficiency 
• Increased exercise tolerance 
• Decreased number of hospitalizations
• Improvement in quality of life
• Increased survival
It should also be noted that the LTHOT is preferable to 
maintaining the child in the hospital, due to lower risk of 
infection, minimized psychological impact of prolonged 
hospitalization, improved quality of life, and decreased 
costs of treatment.10-14
Characteristics of long-term home oxygen 
therapy in children
Children present very specific characteristics regarding the 
indication, discontinuation, and maintenance of oxygen 
therapy; thus, the recommendations for adults do not apply 
to them. The main differences of LTHOT in children when 
compared to adults are:10-14
•  Physical growth and neurological development must be 
considered.
•  The evolution of some diseases that cause hypoxemia in 
children is generally good; many children require LTHOT 
only for a limited period of time.
•  Most clinical conditions in children are characteristic to 
this age group, although older children and adolescents 
may have indications similar to those in adults.
•  The indication and monitoring of oxygen use are per-
formed by pulse oximetry and not by blood gas analysis.
•  Specific equipment is necessary to allow for low oxygen 
flow.
•  Many children need oxygen only at night, thus requiring fewer 
than the 15 hours recommended for LTHOT in adults.
• All children require adult supervision.
•  Oxygen therapy should be provided at schools for school-
age children.
Sources of oxygen
There are three possible sources for oxygen therapy at 
home: cylinders, oxygen concentrators, and oxygen in the 
liquid form (Figure 1), each with advantages and disadvan-
tages.15,16
Pressurized gas cylinders
The cylinder stores the pressurized gas, thus providing 
100% O2. It presents as a major limitation the need to 
be changed frequently, as the largest available cylinder 
provides continuous O2, with a 2 L/min flow, for only 75.5 
hours. Portable cylinders can provide continuous O2, with a 
flow of 2 L/min, for 5 hours. 
Liquid oxygen
Liquid O2 is stored in adequate devices (cryogenic tanks) 
and maintained at a temperature of –196°C. Each liter of 
liquid O2 produces 863 liters of O2 in gas form, which is then 
supplied as 100% O2. The tanks have the capacity to hold 
25 to 40 liters of liquid O2. Thus, a tank with the capacity 
of 40 liters provides 33,600 liters of gaseous O2, supplied 
continuously at a flow rate of 2 L/min for 11 days. Portable 
containers are available with autonomy of up to 8 hours, 
and are the best option to allow ambulation.
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There are now electronic devices that release the gas 
only during inspiration, substantially reducing the losses 
that occur with continuous flow, decreasing the need for 
refills. However, they are not recommended for small 
children due to lack of system activation by the child’s 
spontaneous breathing.17 The main disadvantage of liquid 
oxygen is its high cost. 
Concentrators
Concentrators filter the air by removing nitrogen and 
increasing O2 concentration. The percentage of O2 provided 
will depend on the used flow, as described in Table 1.
It has the advantages of being the easiest source to 
handle, occupying less space, and not requiring refills. 
Recently, portable concentrator models have been devel-
oped, aimed at facilitating patient ambulation.
Its main disadvantage is requiring electricity, which is an 
additional cost to the treatment. However, the cost can be 
up to 55% lower than that of cylinders.4
Table 2 summarizes the advantages and disadvantages of 
each O2 source. 
General considerations on the equipment
For children, the preference is for the use of concentra-
tors, while maintaining a large volume cylinder in case of 
power failure. Concentrators provide flow of 1 to 4 L/min, 
and there are low-flow concentrators that provide flow 
from 0.1 to 1 L/min. Currently, there are concentrators 
that run on batteries in case of power failure. 
When the required flow is less than 0.3 L/min. and the 
estimated duration of the LTHOT is less than 3 months, 
cylinders are the best option. It is important to recall that 
a flow < 0.25 L/min is not possible with liquid oxygen. For 
patients that require oxygen 24 hours/day, it is always nec-
essary to have a portable way to supply it (small cylinders, 
liquid oxygen, or portable concentrator). 
It is worth mentioning that LTHOT in Brazil has been 
regulated differently by diverse state and/or municipal 
health secretariats, which should provide this service to 
patients who have an indication for its use. 
Oxygen administration forms
Oxygen should be provided preferably by nasal cannula; the 
use of oxygen masks may be exceptionally considered. The 
nasal cannula should be changed every one to two months, 
and the masks, every six to 12 months. In children with 
tracheostomy, oxygen should be administered through an 
appropriate mask for tracheostomy.13 
Humidification must be considered when oxygen is sup-
plied in flows greater than 1 L/min, and it is always indi-
cated for patients with CF.13
Principles of pulse oximetry
Pulse oximetry, not arterial blood gas, is used in children 
as a parameter to indicate LTHOT. It is important to know 
the basics of this method, as well as the oxygen saturation 
levels by pulse oximetry (SpO2) levels considered normal in 
children. 
Pulse oximetry uses the principle of spectrophotometry, 
whereby each substance absorbs light in a specific way. The 
most commonly used pulse oximeters emit red (660 nm) and 
infrared (940 nm) light on one side of the sensor, and on 
the other side, capture the unabsorbed fraction of emitted 
light for each wavelength. Only the light that corresponds 
to the pulsatile mass, i.e., arterial blood, is analyzed. The 
Figure 1 Sources of oxygen (gas cylinder, oxygen concentrator, and liquid oxygen).
Table 1 Percentage of oxygen released by the 
concentrator.
Used flow Percentage of oxygen
≤ 2 L/min ≥ 95%
3 a 5 L/min ≥ 90%
> 5 L/min < 90%
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oxyhemoglobin absorbs infrared light preferentially, and 
reduced hemoglobin, the red light. Based on this differ-
ence, and comparing with reference values found in the 
population, the device calculates the SpO2 levels.
18,19 
Dysfunctional hemoglobins, such as carboxyhemoglobin 
and methemoglobin, may distort the results, as they absorb 
light at wavelengths that overlap those absorbed by oxyhe-
moglobin and reduced hemoglobin. In recent years, a pulse 
co-oximeter (fractional oximetry) that emits a greater 
number of wavelengths has been developed, and has the 
advantage of differentiating these hemoglobins. The SpO2 
measured by co-oximetry usually shows a difference of 
approximately 2% less when compared to traditional oxim-
etry. In situations where there is increased dyshemoglobins, 
the co-oximeter is the noninvasive method of choice for 
a more precise assessment.20 Fetal hemoglobin does not 
interfere with saturation measurements performed with 
the pulse oximeter, making this assessment reliable in 
neonates.18
Regarding the accuracy of pulse oximeters for saturation 
levels above 70%, SpO2 differs by less than 3% from SaO2 
(arterial O2 saturation). 
Factors that can alter SpO2:
19
• SaO2 < 70%.
•  Ambient light: intense sunlight or fluorescent light can 
decrease the values.
• Movement artifact.
• Sensor malposition: can increase or decrease the values.
•  Pigments: very dark skin or dark nail polish can underesti-
mate saturation values; high levels of bilirubin (> 20 mg/
dL) can overestimate SpO2.
• Intravascular dyes such as methylene blue.
• Hypoperfusion: shock, hypovolemia, and hypothermia.
• Peripheral vasoconstriction triggered by cold.
•  Venous congestion: can originate venous pulses, which 
mislead the equipment. Venous pressure can increase 
with the use of cuffs, tourniquets, etc.
• Anemia: extreme cases can produce false results.
• Edema: due to light dispersion in edematous tissue.
The most often used site to measure oximetry is the tip 
of the finger. In children, the toe can be used, or even the 
foot in small infants. There are different sizes and types 
of sensors, and it is important that it fits the site where 
it will be used. The plethysmographic pulse wave is an 
important resource for the assessment of adequate sensor 
adaptation.18,19
Normal values of pulse oximetry
Healthy children younger than 1 year
Three longitudinal studies have investigated SpO2 in children 
younger than 12 months. The study by Hunt et al.21 found a 
median SpO2 of 98% during sleep, considering only periods 
with regular breathing. SpO2 did not vary with age (2 to 25 
weeks old). The median number of desaturation episodes 
was four (one to 71), they were associated with apnea or 
periodic breathing, and decreased with age. A more recent 
study by the same group found no difference in basal 
SpO2 between preterm and term infants. The desaturation 
episodes were more common in preterm infants up to 43 
weeks of postconceptional age, when values were equal 
to those of full-term newborns.22 The study by Masters et 
al.23 identified a slight increase in basal saturation and a 
decrease in the time and number of desaturation episodes 
up to 6 months of age. 
Cross-sectional studies, performed during sleep in the 
first two months of life and restricted to periods of regu-
lar breathing, found mean SpO2 from 97.6% to 100%, even 
when preterm infants (without lung disease) were includ-
ed.24-27 The mean percentage of time with saturation < 90% 
in healthy term infants ranged from 0% to 2%,21,23,28 and in 
premature infants it was 2.5%.29 
Based on several studies, it can be concluded that the 
mean basal SpO2 in healthy infants during the first year of 
life is approximately 97% to 98%.13 It is noted, however, 
that a small percentage of normal children can present 
lower SpO2 values, especially if the periods of irregular and 
Table 2 Sources of oxygen.
Type Advantages Disadvantages
Pressurized gas cylinder Widely available High cost
 Does not require electricity Heavy and large
  Risk of falling and causing accidents
  Needs frequent refills
  Hinders ambulation
Liquid oxygen  Allows ambulation High cost
 Does not require electricity Risk of burns during recharging
  Needs refills
  Available only in major cities
Concentrators Widely available Needs electricity
 Unlimited volume of gas Does not provide 100% oxygen
 Low cost 
 Easy handling 
 Smaller size
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periodic breathing, which are frequent in young infants, 
are included.
Healthy children older than one year
A study carried out in children between 2 and 18 years 
found a median basal SpO2 of 99.5% (5
th percentile: 96.6%). 
The desaturation episodes had a frequency of 0.6/hour.30 
In elementary schoolchildren, another study showed a 
median SpO2 of 97.9% (95 to 100). The median number of 
desaturation episodes > 4% was 0.8/hour.31 Based on these 
studies, it can be concluded that the median basal SpO2 in 
healthy children older than 1 year is approximately 98% (5th 
percentile: from 96% to 97%).13
Main indications for long-term home oxygen 
therapy in children and adolescents
Bronchopulmonary dysplasia
The term BPD, or chronic lung disease in preterm infants, 
no longer refers to a unique clinical entity which is clini-
cally/anatomically and physiopathologically defined. The 
disease as originally described by Northway in 1967, a 
severe chronic lung disease that affected preterm infants 
with hyaline membrane syndrome undergoing prolonged 
and aggressive mechanical ventilation, practically no lon-
ger occurs.32 
Medical knowledge of the major determinants of this 
clinical picture and improvement in neonatal care have 
changed the course of the disease.33 Currently, the sur-
vival of extremely preterm infants, with lung immaturity at 
higher grades that also develop into chronic lung disease, 
has become a reality. In this “new” BPD, a lower degree of 
airway injury can be observed, but with altered alveolar 
architecture, dysmorphic pulmonary microvasculature, and 
varying degrees of interstitial involvement.34 Therefore, 
currently, BPD is the diagnosis of premature newborns who, 
with 36 or more weeks of corrected gestational age (CGA), 
and at least 28 days of postnatal age, still need oxygen.35,36 
Many of them will be dependent on oxygen for months or 
years, thus making BPD the most frequent indication for 
LTHOT in children.10 
Several aspects must be considered for oxygen supple-
mentation in preterm infants:
•  It is estimated that a fetus maintains normal intrauterine 
growth with an arterial saturation of 70%.17 
•  Normal basal SpO2 for healthy newborns (term and pre-
mature > 33 weeks of CGA) presents mean values of 97% 
to 99%.14,27,37
•  Continuing moderate hypoxia is associated with the 
development of pulmonary hypertension, increased air-
way resistance, growth deficit, increased risk of sudden 
death, and possible neurodevelopmental problems.13,14 
•  High arterial oxygen concentrations can lead to tissue 
damage in the retina, brain, and lungs in premature 
infants in animal and human studies.13,17
•  It is yet to be determined which parameters related to the 
use of O2 are the most significant in the genesis of diseases 
associated with its use in premature infants: degree of 
immaturity, oxygen fraction in inspired air, blood concen-
tration of O2, SpO2 instability, or time of use.
Two important studies guide the references related to 
the use of long-term oxygen therapy in BPD:
•  A study known as STOP-ROP (Supplemental Therapeutic 
Oxygen for Prethreshold Retinopathy of Prematurity) 
evaluated the development of prematurity retinopathy in 
649 neonates (mean of 35 weeks post-menstrual age) who, 
for at least two weeks, were monitored for maintenance 
of SpO2 between 89% and 94%, or between 96-99%. It was 
observed, at 3 months of CGA, that the group receiving 
higher SpO2 presented a greater incidence of adverse 
events of pulmonary origin, and a greater percentage of 
children remained dependent on oxygen and diuretics.38 
•  The BOOST (Benefit of Oxygen Saturation Targeting) study 
followed 358 preterm infants who still required supple-
mental oxygen at 32 weeks of post-menstrual age. They 
were divided into two groups according to SpO2 mainte-
nance target (91% to 94% or 95% to 98%), and were evalu-
ated at 12 months of CGA. There were no differences 
regarding growth or neuropsychomotor development 
between the two groups; however, the group with higher 
supplementation needed oxygen for a longer period 
of time and a higher percentage of children remained 
dependent on O2 at 36 weeks of CGA. The largest number 
of deaths from pulmonary causes was observed in the 
group with high saturation target (although not statisti-
cally significant).39
Since then, lower SpO2 target levels in the treatment 
of BPD have been recommended. However, it must be 
emphasized that the higher incidence of lung diseases in 
the group with high target saturations observed in the 
STOP-ROP study can be associated with a direct toxic effect 
of oxygen, as a greater fraction of O2 in inspired air was 
used in some of these patients. This can be controlled in 
LTHOT situations, with O2 flow limitation dispensed via the 
nasal cannula. It should be noted, too, that the population 
evaluated in the BOOST study was much younger than the 
children with BPD eligible for LTHOT.37 
Further studies are needed to confirm these findings, as 
well as assessments of long-term effects of mild hypoxemia 
and of prolonged artificial maintenance of normal levels 
of SpO2. 
LTHOT is indicated for patients with clinically stable BPD 
who remain dependent on O2 (saturation in ambient air ≤ 
92%) and who do not present hypercarbia. There is no con-
sensus on what should be the desired saturation of LTHOT 
in BPD. It is recommended to maintain SpO2 ≥ 93% without 
frequent fluctuations (during sleep or feeding); high flows 
of O2 and hyperoxia should be avoided (SpO2 ≥ 99%). One 
exception is when the child already has associated pulmo-
nary hypertension, in which case the saturation should be 
maintained > 95%. 
In addition to the already mentioned physiological and 
clinical benefits of LTHOT, the following should be empha-
sized in BPD: reduced airway resistance, reduced intermit-
tent desaturations, reduced risk of sudden death, and better 
physical growth and neurological development.8,10,13,14,40-43 
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The long-term prognosis of these patients is usually 
good, and the time of supplemental oxygen use should be 
evaluated individually, ranging from a few days to months 
or years.14,44,45 Comorbidities must always be reassessed 
(malnutrition, heart disease, pulmonary hypertension, 
infection) if the oxygen requirement increases or is extend-
ed for too long. 
Cystic fibrosis
There is insufficient evidence to establish the ideal time 
to indicate LTHOT in patients with CF, as its benefits are 
not well established: some studies show improvement 
in attendance and performance at school and work and 
in exercise duration, but no changes in hospitalization, 
disease progression, and mortality. It has been estimated 
that approximately 1% to 2% of children with CF receive 
LTHOT.10,13,46-49 
Episodes of hypoxia in CF patients may occur during 
sleep, exercise, air travel, and infectious exacerbations, 
and are not limited to severe patients. Hypoxia during 
sleep and exercise may occur in stable patients who do not 
have hypoxia during the day.50,51 The deleterious effects 
of hypoxia in patients with CF are numerous: pulmonary 
hypertension, worsening of pulmonary infection and inflam-
mation, reduced exercise capacity and muscle strength, 
and worsening of quality of sleep and quality of life. 
As the indications for LTHOT in CF are not well estab-
lished, the same criteria used to indicate oxygen therapy in 
COPD is suggested, especially in older CF patients, i.e.: PaO2 
≤ 55 mmHg or SpO2 ≤ 88% or PaO2 between 56-59 mmHg or 
SpO2 = 89% associated with signs suggestive of cor pulmonale 
or presence of congestive heart failure or polycythemia (HT 
> 56%).16 In infants and preschoolers with CF, supplemental 
oxygen is recommended according to the criteria used for 
BPD, that is, when the SpO2 is < 93%. This earlier-onset oxy-
gen supplementation aims primarily to optimize weight and 
height development and to prevent pulmonary hypertension. 
The desired SpO2 with oxygen therapy in older patients with 
more severe disease must be equal to or slightly greater than 
90%, avoiding excessive increases of saturation due to the 
risk of hypercapnia.10,13,49
Regarding the presence of hypoxia during sleep in CF, 
some authors have demonstrated that when resting SpO2 is 
< 93%-94%, there is a great risk of desaturation occurring 
during sleep.52 Another study in Brazil, evaluating 40 CF 
patients with and without significant pulmonary involve-
ment, showed that forced expiratory volume in one second 
(FEV1) < 64% is a good predictor of desaturation during 
sleep, with good sensitivity and specificity.51 These data 
suggest that when FEV1 is around 60% and/or SpO2 levels 
during wakefulness are < 94%, nocturnal hypoxia may be 
occurring. In this situation, whenever possible, an oximetry 
measurement should be performed during sleep or even a 
polysomnography, to document the presence and degree of 
nocturnal hypoxemia; if supplemental oxygen is indicated, 
this information can guide the titration of O2 at night. The 
use of oxygen therapy during sleep may facilitate sleep 
onset; however, there is no evidence of improvement in the 
quality of sleep.49
During exercise, desaturation is considered when 
there is a decrease of 4% or more in basal SpO2; in this 
situation, oxygen supplementation during exercise and/
or pulmonary rehabilitation should be considered, and 
may lead to improvement in exercise duration and per-
formance.53 
There is still much controversy about the real benefits of 
oxygen therapy on the morbimortality of CF patients, which 
is often seen as having only a palliative effect. Therefore, 
the ideal time for LTHOT indication should be thoroughly 
evaluated considering the psychological impact of this pre-
scription, as it indicates disease worsening to the patient. 
It should be reserved mainly for patients who, in addition 
to meeting the laboratory criteria, also show symptom 
relief with its use. 
Non-cystic fibrosis bronchiectasis
LTHOT indication for patients with bronchiectasis due to 
other causes follows the same criteria of those for CF.13,14
Bronchiolitis obliterans
Bronchiolitis obliterans, usually secondary to viral infec-
tions, is a cause of severe COPD in infants. It is often 
accompanied by hypoxemia and need for LTHOT during 
varying periods. There are no established oxygen saturation 
levels for the start of LTHOT in these patients. The use of 
the same criteria used in children with BPD (SpO2 < 93%) is 
suggested, as it predominantly affects infants.13,54,55
Interstitial lung diseases
Interstitial lung diseases represent a rare and diverse group 
of lung diseases in children, where gas exchange is often 
compromised by the presence of hypoxemia. Therefore, 
many of these patients require LTHOT for varying periods, 
associated with drug therapy.13,56-58
Idiopathic pulmonary hypertension
The advent, in recent years, of several new specific pul-
monary vasodilator agents has changed the management 
of idiopathic pulmonary hypertension (IPH), and there has 
been an improvement in survival of these patients.59,60 
There are no data confirming the benefits of continuous 
oxygen therapy for patients with IPH.59-61 However, some 
patients with normal oxygen saturation at rest may have 
desaturations during sleep due to hypoventilation and 
also due to decreased lung volumes, with increased shunt 
fraction; in this situation, nocturnal oxygen therapy can 
help prevent desaturations through the pulmonary vasodi-
lation. Other situations in which desaturations can occur 
are during exercise and during episodes of upper airway 
infection, in which oxygen use may also be necessary. In 
view of these considerations, the availability of oxygen 
at home must be evaluated individually in these patients, 
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and LTHOT should be considered when there is evidence of 
symptom relief or reversal of desaturation during exercise 
and/or sleep.13,14 
Pulmonary hypertension secondary to lung 
disease
Pulmonary hypertension secondary to lung disease results 
from chronic alveolar hypoxia and considerably worsens the 
prognosis of the underlying disease. Chronic hypoxia leads 
to pulmonary vasoconstriction and endothelial dysfunction. 
Moreover, the pulmonary circulation is more reactive to 
hypoxia in children than in adults.62 In these cases, oxygen 
is the most potent pulmonary vasodilator, and LTHOT can 
slow down and even reverse the alterations in the pulmo-
nary vascular bed induced by hypoxia, and may contribute 
to improvement of survival.13,63 
Congenital heart diseases
Home oxygen therapy is not indicated in cyanotic heart 
diseases. Cyanosis is a consequence of the decrease in 
pulmonary blood flow or of ineffective flow, such as par-
allel circulation or mixing of venous and arterial blood. 
Therefore, oxygen has little effect in increasing the SaO2, 
and only polycythemia can be reduced.13
Pulmonary hypertension secondary  
to congenital heart diseases
PH secondary to congenital heart disease (Eisenmenger’s 
syndrome) is refractory to oxygen, and there is controversy 
as to whether its use can improve patient survival.64,65 In 
the final stages of PH, oxygen can provide symptomatic 
relief in children with severe right congestive heart failure 
and resting hypoxemia.13 Children with congenital heart 
disease awaiting surgery (without Eisenmenger’s syndrome) 
and increased pulmonary artery pressure responsive to 
oxygen can benefit from home oxygen therapy, as well as 
children recovering from the surgery.14 
Intrapulmonary right-left shunt
Intrapulmonary shunt, usually due to arteriovenous malfor-
mations, is a cause of hypoxia. As alveolar oxygen levels 
are not affected, the impact on the pulmonary vasculature 
is lower than in other lung diseases. However, the impact of 
the low SaO2 on other systems is unknown. In some cases, 
LTHOT can improve neurological development, diurnal 
activities, and other symptoms, despite the slight increase 
in saturation levels.13
Obstructive sleep apnea syndrome
The first line of treatment for obstructive sleep apnea 
syndrome (OSAS) in children consists of surgical removal 
of tonsils and adenoids.66 In cases of postoperative residual 
OSAS, when surgery is impossible or when other factors 
are responsible for the clinical picture, continuous positive 
airway pressure (CPAP) or noninvasive ventilation (NIV) is 
indicated.67 LTHOT indication is restricted to severe cases, 
usually associated with hypoventilation, in which, despite 
the use of NIV, hypoxemia persists. Another indication for 
LTHOT occurs in extreme cases, when none of the above 
can be used. Oxygen can then minimize oxyhemoglobin 
desaturation, but will not significantly affect the frequency 
or duration of obstructive events. In these cases, CO2 levels 
should be monitored.68,69 
Chronic hypoventilation
Chronic hypoventilation may have central or peripheral ori-
gin, due to alterations in chest wall structure or respiratory 
muscle weakness (neuromuscular diseases).70,71 The treat-
ment of choice is NIV via face mask or tracheostomy. Oxygen 
therapy can be used in milder and non-progressive cases, 
in cases when NIV use is impossible, and in cases in which, 
despite NIV, patients persist with hypoxemia due to inade-
quate ventilation or the presence of associated lung disease. 
When LTHOT is used alone, CO2 levels must be monitored.
13
Chronic encephalopathies
It is not uncommon for children with chronic encephalopa-
thy to develop chronic hypoxemia and the need for LTHOT. 
This usually stems from multiple factors: recurrent pneu-
monia usually related to aspiration processes secondary 
to gastroesophageal reflux and/or dysphagia, ineffective 
cough, and pulmonary restriction due to scoliosis or other 
chest deformity.13
Sickle-cell anemia
The main objectives of LTHOT in patients with sickle cell 
anemia (SCA) are to prevent stroke episodes, recurrent 
painful crises, and secondary pulmonary hypertension.
When assessing levels of SaO2 as a criterion for recom-
mending LTHOT, it must be considered that its measure-
ment is subject to several sources of error. If a blood 
gas analyzer calculates SaO2 from the PaO2 measurement 
using a standard curve of hemoglobin A dissociation, SaO2 
may be overestimated, as in SCA the curve may shift to 
the right.72,73 If the device measures SaO2 directly through 
co-oximetry, there will be no discrepancy. Pulse oximetry 
is also subject to error, both for superestimation or under-
estimation of the SpO2 levels. In oximetry with two wave-
lengths, there may be an increased value due to the higher 
percentage of carboxyhemoglobin and methemoglobin in 
these patients.74,75 Conversely, SpO2 may be underestimated 
due to the geometry of the red cell, which can disperse 
light differently due to anemia, dark skin color, and inad-
equate perfusion of the extremities.76 
Risk factors suggested for acute painful crisis include 
sickle cell type, severity of anemia, fetal hemoglobin con-
03 Rev 6-17.indd   13 6/3/13   08:52:12
14 Adde FV et al.
centration, and hypoxemia. Several authors defend that 
hypoxemia is not the most important factor, emphasizing 
that the level of hemoglobin S favors deoxygenation and 
polymerization, even with adequate levels of PaO2.
72,77 
Other studies, however, showed that the mean low noctur-
nal saturation was associated with increased risk of painful 
crisis and stroke episodes.78,79 
Considering these data, it is suggested that SpO2 should 
be measured during wakefulness and sleep, and when 
< 93%, PaO2 should be measured through arterial blood. 
If PaO2 is < 70 mmHg, LTHOT can be considered. Other 
clinical data, such as hemoglobin level, the percentage 
of hemoglobin S and fetal hemoglobin, the frequency of 
vaso-occlusive crisis, and the neurological and pulmonary 
involvement should be assessed simultaneously.
Palliative care
In adults with terminal cancer, it is controversial whether 
oxygen therapy alleviates the sensation of dyspnea. In chil-
dren, there are no data on the management of terminal 
dyspnea, but in some cases there may be benefits with 
oxygen, as chronic hypoxia can cause irritability, headache, 
and restlessness. When indicated, the use of nasal cannula 
should be preferred, so as not to cover the child’s face 
with a mask. The management of these cases should be 
individualized and if, together with the patient and family, 
symptom relief is observed, LTHOT should be used.13,14 
Long-term home oxygen therapy versus 
noninvasive ventilation
It is important to differentiate patients with chronic 
hypoxemia from those in which NIV is the most appropriate 
treatment. The diseases that lead to alveolar hypoventila-
tion, such as central nervous system disorders, neuromus-
cular disorders, diseases of the chest wall, and obesity 
hypoventilation syndrome are indications for NIV with two 
levels of pressure.70 CPAP is mainly indicated for OSAS, 
although its use in CF has resulted in improved SpO2 during 
sleep.80 In parenchymal lung diseases, such as CF and bron-
chiolitis obliterans, NIV has been used sporadically in the 
advanced stages, in exacerbations, and when LTHOT leads 
to hypercapnia.80,81
Prerequisites for the indication of long-term 
home oxygen therapy
Before indicating LTHOT, some points should be considered, 
particularly in cases of BPD:10,13
•  The need for oxygen must be stable, and saturation 
should stay at 93% or higher, without the frequent occur-
rence of desaturation episodes. The saturation should not 
fall below 90% for more than 5% of the time.
•  Babies should be able to withstand short periods in ambi-
ent air, without the risk of rapid deterioration, in case of 
disconnection of the nasal cannula.
•  There should be no other medical condition that impairs 
LTHOT, and the child should be stable and presenting 
satisfactory growth. There must not have been episodes 
of apnea for a period of two weeks.
•  An echocardiogram is recommended in order to assess the 
presence of PH.
• The immunization schedule must be up to date.
•  Parents/caregivers must want and be comfortable with 
returning the child home on oxygen therapy; they must 
be trained on LTHOT use and should be able to identify 
problems related to oxygen administration.
• The home environment should be satisfactory, and should 
be evaluated before hospital discharge.
General guidelines for long-term home oxygen 
therapy in children
•  No smoking inside the house, and parents/caregivers must 
be warned against the danger of oxygen in contact with 
fire, such as candles, stove burners, and cigarettes.
•  Older children should be instructed on how to use their 
oxygen equipment.
•  Parents must be educated regarding the transportation of 
oxygen during travel. During air travel, the airline must 
be informed in advance.
•  Parents must know with whom to communicate or where 
to go in case of emergencies, and must be able to iden-
tify empty cylinders, displaced cannulas, and blocked 
valves.
Long-term home oxygen therapy prescription
The titration of the oxygen flow should be performed at a 
time of clinical stability and at rest. Whenever possible, it 
should also be performed at feeding time in infants, during 
exercise in older children, and during sleep when there is 
suspicion of nocturnal desaturation.
SpO2 in ambient air should be measured and recorded 
for at least six hours in hospitalized children. For outpa-
tients, a measurement of at least 15 minutes is recom-
mended. The titration is then started with low flows of 
oxygen (0.1 to 1 L/min) and after, if necessary, the flow 
can be increased by half liters until the desired satura-
tion is attained, which will be the flow recommended 
for home use. The maximum tolerated flow through a 
nasal cannula is generally 4-5 L/min. It is common for 
infants with BPD to require very low O2 flow (< 0.5 L/
min.). In adults with COPD, the empirical addition of 1 
L/min in the evening to the basal O2 flow when oximetry 
during sleep cannot be performed is recommended.16 
This recommendation can be adopted for older children 
and adolescents.
LTHOT prescription must be made by the general or pedi-
atric pulmonologist, and it must include the recommended 
oxygen source, mode of administration (nasal cannula, face 
mask, or tracheostomy), flow of O2, and the period of use 
(day and/or night and/or during exercise). 
The follow-up of patients on LTHOT should be carried out 
as follows: the first return consultation must be approxi-
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mately within one month, and subsequent evaluations 
should be performed every two months in children with BPD 
and every four to six months in other clinical situations. 
In these reevaluations, it is necessary to verify the use of 
home oxygen therapy and to reevaluate SpO2 in ambient air 
and with oxygen, maintaining or modifying the prescription 
of LTHOT. 
It should be noted that there is no formal indication for 
continuous pulse oximetry monitoring in the home environ-
ment.13 
Long-term home oxygen therapy weaning
Weaning patients from LTHOT is more relevant for patients 
with BPD, where there is usually a progressive improve-
ment in the lung disease. There are few other clinical con-
ditions in which it may be possible to remove the oxygen; 
it is sometimes possible in cases of interstitial pulmonary 
diseases and bronchiolitis obliterans. 
Once the oxygen requirement reaches 0.1 L/min, 
weaning should be considered; the same saturation tar-
get used when LTHOT was instituted should be used for 
discontinuation (usually when the SpO2 in ambient air 
is stable and above 93%). Children who needed oxygen 
24h/day may at first use it only during sleep and meals. 
In some cases, total weaning can be accomplished all at 
once. The equipment used for LTHOT must remain in the 
residence for at least three months after the withdrawal 
or discontinuation. After oxygen therapy discontinua-
tion, oximetry control must be carried out on two occa-
sions approximately one month apart, and if it remains 
adequate, the oxygen equipment may safely be removed 
from the residence.13,14 
Long-term home oxygen therapy failures
LTHOT failure is defined as the persistence/worsening of 
hypoxemia and dyspnea, exercise intolerance, decompen-
sated cor pulmonale, and high hematocrit maintenance. 
The causes may be: lack of a suitable LTHOT program, 
which includes portable equipment; non-adherence to 
LTHOT due to insufficient information and/or for esthetic/
social reasons, especially in adolescents; worsening/pro-
gression of the underlying disease or interruption of drug 
treatment; associated diseases.16
Conclusions
The use of LTHOT is increasingly common in children and 
adolescents; its indications are numerous and its use will 
tend to increase in the coming years, especially in BPD 
and CF. It has very relevant particularities when compared 
to adult LTHOT. Although there have been few studies 
on LTHOT in pediatric patients, there is already enough 
evidence to ensure its proper indication. Further studies 
are needed to assess the best time to indicate LTHOT in 
different clinical situations and its role in the quality of 
life and survival of these patients.
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